This is an observational study in which all participants will be given semaglutide. There will be no randomization and no placebo.
Participants will be in the study for 12 months (+/- 2 months) depending on when they reach the maintenance dose of semaglutide.
Blood and urine will be maintained by the principal investigator indefinitely. Identifiers will be removed from the samples.
Approximately 50 patients will be enrolled.
The study drug, Ozempic, is FDA approved.
